Histamine H3 receptor Inhibitors
1 drugsAbout Histamine H3 receptor
The Histamine H3 receptor (H3R) is a G protein-coupled receptor that binds histamine, primarily functioning as a presynaptic autoreceptor and heteroreceptor in the central nervous system. It regulates the release of histamine and other neurotransmitters like dopamine and serotonin. This regulatory role makes H3R a drug target for neurological and psychiatric conditions.
Currently, there is no genetic evidence available linking the Histamine H3 receptor to specific diseases. However, the H3 receptor's influence on neurotransmitter release suggests potential applications in areas such as sleep disorders and cognitive enhancement.
There is one FDA-approved drug, WAKIX (pitolisant), targeting H3R; it was first approved in 2019. WAKIX is a small molecule and is marketed by HARMONY.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Idiopathic Hypersomnia with only 1 trials.
Top Histamine H3 receptor Drugs
HARMONY is the only company with an approved drug targeting H3R.
The market is not competitive, but HARMONY's dominance creates a high barrier to entry.
Histamine H3 receptor Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Histamine H3 receptor, using small molecule modality.
Explore opportunities for novel modalities like antibodies or biologics to differentiate from existing therapies.
Histamine H3 receptor Clinical Trials 10 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 2 | 2 | 0 | 50% |
| Phase 2 | 1 | 0 | 0 | 1 | - |
| Phase 3 | 5 | 4 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Histamine H3 receptor Drug Approval Timeline (2019 - 2019)
WAKIX was the first and most recent drug approved in 2019.
The approval timeline indicates a nascent market; further clinical validation may drive future approvals.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (12 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 16 clinical trials targeting Histamine H3 receptor.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities